arcutis biotherapeutics inc - ARQT
ARQT
Close Chg Chg %
24.57 -0.36 -1.47%
Pre-Market
24.21
-0.36 (1.47%)
Volume: 894.69K
Last Updated:
Apr 10, 2026, 4:00 PM EDT
Company Overview: arcutis biotherapeutics inc - ARQT
ARQT Key Data
| Open $24.47 | Day Range 23.59 - 24.54 |
| 52 Week Range 11.86 - 31.77 | Market Cap $3.05B |
| Shares Outstanding 124.03M | Public Float 109.33M |
| Beta 1.77 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.13 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.29M |
ARQT Performance
| 1 Week | 2.45% | ||
| 1 Month | 6.42% | ||
| 3 Months | -6.34% | ||
| 1 Year | 92.30% | ||
| 5 Years | -12.03% |
ARQT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About arcutis biotherapeutics inc - ARQT
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
ARQT At a Glance
Arcutis Biotherapeutics, Inc.
3027 Townsgate Road
Westlake Village, California 91361
| Phone | 1-805-418-5006 | Revenue | 376.07M | |
| Industry | Pharmaceuticals: Major | Net Income | -16,141,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 91.344% | |
| Fiscal Year-end | 12 / 2026 | Employees | 354 | |
| View SEC Filings |
ARQT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.825 |
| Price to Book Ratio | 18.902 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -523.004 |
| Enterprise Value to Sales | 9.54 |
| Total Debt to Enterprise Value | 0.032 |
ARQT Efficiency
| Revenue/Employee | 1,062,350.282 |
| Income Per Employee | -45,596.045 |
| Receivables Turnover | 2.572 |
| Total Asset Turnover | 0.962 |
ARQT Liquidity
| Current Ratio | 3.167 |
| Quick Ratio | 2.993 |
| Cash Ratio | 1.704 |
ARQT Profitability
| Gross Margin | 90.243 |
| Operating Margin | -3.251 |
| Pretax Margin | -3.981 |
| Net Margin | -4.292 |
| Return on Assets | -4.129 |
| Return on Equity | -9.303 |
| Return on Total Capital | -5.315 |
| Return on Invested Capital | -5.663 |
ARQT Capital Structure
| Total Debt to Total Equity | 60.284 |
| Total Debt to Total Capital | 37.611 |
| Total Debt to Total Assets | 26.382 |
| Long-Term Debt to Equity | 59.756 |
| Long-Term Debt to Total Capital | 37.281 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Arcutis Biotherapeutics Inc - ARQT
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 3.69M | 59.61M | 196.54M | 376.07M | |
Sales Growth
| - | +1,517.09% | +229.74% | +91.34% | |
Cost of Goods Sold (COGS) incl D&A
| 1.70M | 6.12M | 19.13M | 36.70M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.25M | 1.88M | 2.60M | 5.37M | |
Depreciation
| 941.00K | 1.13M | 640.00K | 700.00K | |
Amortization of Intangibles
| 312.00K | 750.00K | 1.96M | 4.67M | |
COGS Growth
| +122.15% | +260.94% | +212.65% | +91.84% | |
Gross Income
| 1.99M | 53.49M | 177.41M | 339.38M | |
Gross Income Growth
| +360.94% | +2,586.49% | +231.69% | +91.29% | |
Gross Profit Margin
| +54.02% | +89.74% | +90.27% | +90.24% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 303.62M | 294.59M | 305.81M | 351.60M | |
Research & Development
| 182.44M | 110.58M | 76.42M | 77.05M | |
Other SG&A
| 121.18M | 184.01M | 229.39M | 274.55M | |
SGA Growth
| +47.55% | -2.97% | +3.81% | +14.97% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (279.00K) | (139.00K) | - |
EBIT after Unusual Expense
| (301.63M) | (241.10M) | (128.12M) | (12.09M) | |
Non Operating Income/Expense
| 5.82M | 11.79M | 15.89M | 9.20M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 15.65M | 29.71M | 27.17M | 12.08M | |
Interest Expense Growth
| - | +89.83% | -8.56% | -55.52% | |
Gross Interest Expense
| 15.65M | 29.71M | 27.17M | 12.08M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (311.46M) | (259.03M) | (139.39M) | (14.97M) | |
Pretax Income Growth
| -50.93% | +16.83% | +46.19% | +89.26% | |
Pretax Margin
| -8,449.76% | -434.57% | -70.92% | -3.98% | |
Income Tax
| - | 3.11M | 647.00K | 1.17M | |
Income Tax - Current - Domestic
| - | - | - | 273.00K | - |
Income Tax - Current - Foreign
| - | 3.11M | 799.00K | 844.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | (152.00K) | 54.00K | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (311.46M) | (262.14M) | (140.04M) | (16.14M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (311.46M) | (262.14M) | (140.04M) | (16.14M) | |
Net Income Growth
| -50.93% | +15.83% | +46.58% | +88.47% | |
Net Margin Growth
| -8,449.76% | -439.79% | -71.25% | -4.29% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (311.46M) | (262.14M) | (140.04M) | (16.14M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (311.46M) | (262.14M) | (140.04M) | (16.14M) | |
EPS (Basic)
| -5.6596 | -3.7824 | -1.1578 | -0.1269 | |
EPS (Basic) Growth
| -35.50% | +33.17% | +69.39% | +89.04% | |
Basic Shares Outstanding
| 55.03M | 69.31M | 120.96M | 127.23M | |
EPS (Diluted)
| -5.6596 | -3.7824 | -1.1578 | -0.1269 | |
EPS (Diluted) Growth
| -35.50% | +33.17% | +69.39% | +89.04% | |
Diluted Shares Outstanding
| 55.03M | 69.31M | 120.96M | 127.23M | |
EBITDA
| (300.37M) | (239.22M) | (125.80M) | (6.86M) | |
EBITDA Growth
| -45.98% | +20.36% | +47.41% | +94.55% | |
EBITDA Margin
| -8,149.05% | -401.34% | -64.01% | -1.82% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 31.75 | |
| Number of Ratings | 8 | Current Quarters Estimate | 0.049 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 0.336 | |
| Last Quarter’s Earnings | -0.075 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.13 | Next Fiscal Year Estimate | 1.205 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | 0.05 | 0.12 | 0.34 | 1.21 |
| High Estimates | 0.11 | 0.22 | 0.75 | 1.61 |
| Low Estimate | -0.02 | 0.05 | 0.08 | 0.69 |
| Coefficient of Variance | 104.42 | 55.71 | 75.64 | 28.27 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Arcutis Biotherapeutics Inc - ARQT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Arcutis Biotherapeutics Inc - ARQT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 5, 2026 | Todd Franklin Watanabe See Remarks; Director | 823,306 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Latha Vairavan SVP Chief Financial Officer | 70,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Masaru Matsuda See Remarks | 147,003 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Patrick E. Burnett See Remarks | 77,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Patrick E. Burnett See Remarks | 121,150 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.91 per share | 3,138,996.50 |
| Mar 5, 2026 | Patrick E. Burnett See Remarks | 121,295 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.16 per share | 3,051,782.20 |
| Mar 5, 2026 | Patrick E. Burnett See Remarks | 127,401 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Patrick E. Burnett See Remarks | 97,401 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Todd Franklin Watanabe See Remarks; Director | 266,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Todd Franklin Watanabe See Remarks; Director | 785,957 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.91 per share | 20,364,145.87 |
| Mar 5, 2026 | Todd Franklin Watanabe See Remarks; Director | 787,025 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.16 per share | 19,801,549.00 |
| Mar 5, 2026 | Keith R. Leonard Director | 49,175 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $8.63 per share | 424,380.25 |
| Mar 5, 2026 | L. Todd Edwards See Remarks | 77,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | L. Todd Edwards See Remarks | 175,178 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.91 per share | 4,538,861.98 |
| Mar 5, 2026 | L. Todd Edwards See Remarks | 175,281 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.16 per share | 4,410,069.96 |
| Mar 5, 2026 | L. Todd Edwards See Remarks | 178,865 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2026 | Howard G. Welgus Director | 49,744 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.65 per share | 1,275,933.60 |
| Mar 5, 2026 | Keith R. Leonard Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Keith R. Leonard Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 5, 2026 | Keith R. Leonard Director | 22,123 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.39 per share | 561,702.97 |